|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue (Note 20) | ||||
| Gross profit | ||||
| Operating expenses: | ||||
| Research and development (Note 20) | ||||
| Selling and marketing (Note 20) | ||||
| General and administrative (Note 20) | ||||
| Reorganization (Note 21) | ||||
| Transaction-related costs (Note 1d) | ||||
| Total operating expenses | ||||
| Operating loss | ||||
| Change in fair value of warrants | ||||
| Finance income | ||||
| Finance expenses | ||||
| Finance income, net | ||||
| Loss before income taxes | ||||
| Income taxes (tax benefit) (Note 22) | ||||
| Loss | ||||
| Other comprehensive income (loss) (net of tax effect): | ||||
| Amounts that will not be reclassified subsequently to profit or loss: | ||||
| Remeasurement gain (loss) from defined benefit plans | ||||
| Amounts that will be or that have been reclassified to profit or loss when specific conditions are met: | ||||
| Adjustments arising from translating financial statements of foreign operations | ||||
| Total comprehensive loss | ||||
| Basic loss per Ordinary share (Note 23) | ||||
| Diluted loss per Ordinary share (Note 23) | ||||
| Weighted average number of shares outstanding used to compute basic loss per share | ||||
| Weighted average number of shares outstanding used to compute diluted loss per share | ||||
Loading...
